



# Pharmacy and Therapeutics (P&T) Committee Provider Update

FIRST QUARTER 2018



Presbyterian Health Plan, Inc.  
Presbyterian Insurance Company, Inc.

## P&T Committee Decisions effective March 1, 2018

**Dear Healthcare Practitioner:** The Presbyterian Health Plan, Inc., and Presbyterian Insurance Company, Inc., (Presbyterian) P&T Committee meets quarterly to promote the appropriate use of drugs to maintain the Presbyterian formularies and to support our network of practitioners. The P&T Committee met on **Jan. 17, 2018**, and we would like to share with you the decisions made at the meeting that affect our formularies and pharmacy benefits.

Drug Name	Centennial Care	Commercial	Metal Level Plans	Medicare*
<b>Formulary Additions</b>				
<b>Alecensa®</b> (alectinib), 150 mg capsules	PA, QL	Tier 4, PA, QL	2017: Tier 4, PA, QL 2018: Tier 5, PA, QL	Tier 5, PA (new starts), QL, SP
<b>Bydureon® BCise™</b> (exenatide extended-release) injectable suspension, 2 mg/0.85 mL auto-injector	NF	Tier 2, ST, QL	2017: Tier 2, ST, QL 2018: Tier 3, ST, QL	Tier 3, QL
<b>Calquence®</b> (acalabrutinib), 100 mg capsules	PA, QL	Tier 4, PA, QL	2017: Tier 4, PA, QL 2018: Tier 5, PA, QL	Tier 5, PA, QL
<b>diclofenac 1% gel</b> (generic for Voltaren gel) – <i>Added to the Centennial Care formulary.</i>	QL	Tier 3, QL	2017: Tier 3, QL 2018: Tier 4, QL	Tier 4
<b>Fiasp®</b> (insulin aspart injection), 100 units/mL vial or FlexTouch pen	QL	Tier 2, QL	2017: Tier 2, QL 2018: Tier 3, QL	Tier 3, QL
<b>Heplisav-B™</b> [Hepatitis B Vaccine (Recombinant), Adjuvanted] solution for IM injection	AL, QL	\$0, AL, QL	\$0, AL, QL	Tier 3, PA (B vs D)
<b>Juluca®</b> (dolutegravir and rilpivirine), 50-25 mg tablets	QL	Tier 4, QL	2017: Tier 4, QL 2018: Tier 5, QL	Tier 5

\*Medicare formulary changes may be pending approval from Centers for Medicare & Medicaid Services (CMS).

MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required, AL = Age Limit

Drug Name	Centennial Care	Commercial	Metal Level Plans	Medicare*
<b>Formulary Additions (continued)</b>				
<b>KedRab</b> Rabies Immune Globulin (Human) Solution for intramuscular injection	MB	MB	MB	Tier 3
<b>QVAR® RediHaler™</b> (beclomethasone dipropionate), breath activated inhalation aerosol 40 mcg or 80 mcg/actuation	ST	Tier 3, PA	2017: Tier 3, PA 2018: Tier 4, PA	Tier 4
<b>rosuvastatin</b> (generic for Crestor), 5 mg, 10 mg, 20 mg and 40 mg tablets – <i>Added to the Centennial Care formulary.</i>	QL	Tier 1	2017: Tier 1 2018: Tier 2	Tier 4
<b>Shingrix®</b> (Zoster Vaccine-Recombinant, Adjuvanted), suspension for IM injection	AG, QL	\$0, AG, QL	\$0, AG, QL	Tier 3
<b>Verzenio™</b> (abemaciclib), 50 mg, 100 mg, 150 mg and 200 mg tablets	NF	NF	NF	Tier 5, PA, QL
<b>Vyxeos™</b> (daunorubicin and cytarabine), 44-100 mg single dose vial	MB, PA, QL	MB, PA, QL	MB, PA, QL	Tier 5, PA (new starts)
<b>Xeljanz XR®</b> (tofacitinib), 11 mg extended-release tablets	PA, QL, SP	Tier 4, PA, QL, SP	2017: Tier 4, PA, QL, SP 2018: Tier 5, PA, QL, SP	Tier 5, PA, QL
<b>New Generics – Unless otherwise noted, when a generic becomes available, the brand name product will be removed from the formularies.</b>				
<b>abacavir</b> (generic for Ziagen), 20 mg/mL oral solution	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 4
<b>atazanavir</b> (generic for Reyataz), 150 mg, 200 mg and 300 mg capsules	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 5
<b>dapsone</b> (generic for Aczone), 5% gel	PA	Tier 3, PA	2017: Tier 3, QL 2018: Tier 4, QL	NF
<b>efavirenz</b> (generic for Sustiva), 50 mg and 200 mg capsules	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 3
<b>estradiol vaginal cream 0.1 mg/gram</b> (generic for Estrace)	Formulary	Tier 1	2017: Tier 1 2018: Tier 2	Tier 3
<b>fosamprenavir</b> (generic for Lexiva), 700 mg tablet	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 5
<b>glatiramer acetate 40 mg/mL</b> (generic for Copaxone 40 mg/mL)	ST, QL, SP	Tier 4, ST, QL, SP	2017: Tier 4, ST, QL, SP 2018: Tier 5, ST, QL, SP	Tier 5, ST, QL, SP
<b>oseltamivir 6 mg/mL oral suspension</b> (generic for Tamiflu)	QL	Tier 3, QL	2017: Tier 3, QL 2018: Tier 4, QL	Tier 4, QL
<b>sodium phenylbutyrate</b> (generic for Buphenyl), 500 mg tablet	NF	NF	NF	Tier 5, PA
<b>tenofovir disoproxil fumarate</b> (generic for Viread), 300 mg tablets	QL	Tier 4, QL	2017: Tier 4, QL 2018: Tier 5, QL	Tier 3
<b>timolol maleate 0.5% ophthalmic solution</b> (generic for Istalol)	NF	Tier 3	2017: Tier 3 2018: Tier 4	NF

\*Medicare formulary changes may be pending approval from Centers for Medicare & Medicaid Services (CMS).

MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required, AL = Age Limit

Drug Name	Centennial Care	Commercial	Metal Level Plans	Medicare*
<b>Formulary Additions (continued)</b>				
<b>KedRab</b> Rabies Immune Globulin (Human) Solution for intramuscular injection	MB	MB	MB	Tier 3
<b>QVAR® RediHaler™</b> (beclomethasone dipropionate), breath activated inhalation aerosol 40 mcg or 80 mcg/actuation	ST	Tier 3, PA	2017: Tier 3, PA 2018: Tier 4, PA	Tier 4
<b>rosuvastatin</b> (generic for Crestor), 5 mg, 10 mg, 20 mg and 40 mg tablets – <i>Added to the Centennial Care formulary.</i>	QL	Tier 1	2017: Tier 1 2018: Tier 2	Tier 4
<b>Shingrix®</b> (Zoster Vaccine-Recombinant, Adjuvanted), suspension for IM injection	AG, QL	\$0, AG, QL	\$0, AG, QL	Tier 3
<b>Verzenio™</b> (abemaciclib), 50 mg, 100 mg, 150 mg and 200 mg tablets	NF	NF	NF	Tier 5, PA, QL
<b>Vyxeos™</b> (daunorubicin and cytarabine), 44-100 mg single dose vial	MB, PA, QL	MB, PA, QL	MB, PA, QL	Tier 5, PA (new starts)
<b>Xeljanz XR®</b> (tofacitinib), 11 mg extended-release tablets	PA, QL, SP	Tier 4, PA, QL, SP	2017: Tier 4, PA, QL, SP 2018: Tier 5, PA, QL, SP	Tier 5, PA, QL
<b>New Generics – Unless otherwise noted, when a generic becomes available, the brand name product will be removed from the formularies.</b>				
<b>abacavir</b> (generic for Ziagen), 20 mg/mL oral solution	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 4
<b>atazanavir</b> (generic for Reyataz), 150 mg, 200 mg and 300 mg capsules	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 5
<b>dapsone</b> (generic for Aczone), 5% gel	PA	Tier 3, PA	2017: Tier 3, QL 2018: Tier 4, QL	NF
<b>efavirenz</b> (generic for Sustiva), 50 mg and 200 mg capsules	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 3
<b>estradiol vaginal cream 0.1 mg/gram</b> (generic for Estrace)	Formulary	Tier 1	2017: Tier 1 2018: Tier 2	Tier 3
<b>fosamprenavir</b> (generic for Lexiva), 700 mg tablet	QL	Tier 1, QL	2017: Tier 1, QL 2018: Tier 2, QL	Tier 5
<b>glatiramer acetate 40 mg/mL</b> (generic for Copaxone 40 mg/mL)	ST, QL, SP	Tier 4, ST, QL, SP	2017: Tier 4, ST, QL, SP 2018: Tier 5, ST, QL, SP	Tier 5, ST, QL, SP
<b>oseltamivir 6 mg/mL oral suspension</b> (generic for Tamiflu)	QL	Tier 3, QL	2017: Tier 3, QL 2018: Tier 4, QL	Tier 4, QL
<b>sodium phenylbutyrate</b> (generic for Buphenyl), 500 mg tablet	NF	NF	NF	Tier 5, PA
<b>tenofovir disoproxil fumarate</b> (generic for Viread), 300 mg tablets	QL	Tier 4, QL	2017: Tier 4, QL 2018: Tier 5, QL	Tier 3
<b>timolol maleate 0.5% ophthalmic solution</b> (generic for Istalol)	NF	Tier 3	2017: Tier 3 2018: Tier 4	NF
<b>Other Formulary Changes: Criteria Updates, Formulary Removals, and Tier Placement Changes</b>				

\*Medicare formulary changes may be pending approval from Centers for Medicare & Medicaid Services (CMS).  
MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required, AL = Age Limit

You can find Presbyterian formularies and updates, including restrictions (e.g., quantity limits, step therapy and prior authorization criteria) and preferences online at:  
<https://www.phs.org/providers/formularies/Pages/default.aspx>

Current and past issues of the Pharmacy & Therapeutics (P&T) Committee Provider Updates are available online at: <https://www.phs.org/providers/contact-us/news-and-communications/Pages/default.aspx>

Providers must register with Presbyterian to receive the Pharmacy & Therapeutics (P&T) Committee Provider Update via email. Presbyterian eNews registration is located at: <https://www.phs.org/providers/contact-us/news-and-communications/Pages/default.aspx>

The Universal Practitioner and Provider Manual and the Centennial Care Practitioner and Provider Manuals are also available online at <https://www.phs.org/providers/resources/training-education/Pages/outreach.aspx> and include information about pharmacy benefits, the prior authorization process, generic substitution and requesting non-formulary medications based on medical necessity. A printed copy of the Centennial Care Practitioner and Provider Manual is available at no cost from Presbyterian by contacting your Provider Network Management relationship executive.

### Formulary Search App


As a reminder, Presbyterian formularies are also accessible through the Managed Markets Insights & Technology, LLC (MMIT) Formulary Search App. No registration, username or passwords are required. Search from your desktop at [www.FormularyLookup.com](http://www.FormularyLookup.com) or download the free app today.

## Formulary Search

#1 drug formulary app on the web



**“Take the guesswork out of selecting medications for your patients and reduce staff time spent on getting authorizations”**



## Requests for Formulary Additions, Deletions or Modifications

Use the **Formulary Addition Request form** to request medication additions, deletions or other changes to the Presbyterian formularies. Complete and submit the form to the ASK PHP P&T mailbox at [askphppt@phs.org](mailto:askphppt@phs.org). The form can be accessed at: [http://docs.phs.org/idc/groups/public/documents/communication/pel\\_00251399.pdf](http://docs.phs.org/idc/groups/public/documents/communication/pel_00251399.pdf)

## Food and Drug Administration (FDA) Alerts from October 2017 to January 2018.

For a full list of FDA alerts and additional information, see the FDA website at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts>

- **Octagam [Immune Globulin Intravenous (human)] 10 percent liquid preparation – Voluntary Market Withdrawal [Oct. 23, 2017]:** Octapharma USA recalled lot numbers K724B8541 & K725A8541. No reports of injury were reported at the time of the recall, but the manufacturer made the decision to suspend further administration of Octagam 10 percent from these particular production lots after consulting the FDA. Octagam is a non-preferred IVIG product on Presbyterian formularies (Flebogamma or Gamunex-C are covered).
- **Uloric (febuxostat) – Drug Safety Communication [Nov. 15, 2017]:** Preliminary results of a safety study show an increased risk of heart-related death with Uloric compared to another gout agent, allopurinol. The Uloric drug label already carries a warning/precaution regarding cardiovascular events, such as heart attacks, strokes and heart-related death. The FDA will update the public with any new information after a comprehensive review of the safety study. Uloric currently requires prior authorization for coverage on all Presbyterian formularies. Patients must have tried and failed allopurinol or have a contraindication to using allopurinol.
- **Riomet (metformin hydrochloride oral solution) – Recall [Nov. 27, 2017]:** Sun Pharmaceuticals recalled the following Riomet products: NDC Code 10631-206-01 Lot A160031A, Exp.: Jan. 2018, and NDC 10631-206-02 Lot: A160031B, Exp.: 01/2018. These affected lots were recalled due contamination with *Scopulariopsis brevicaulis*, which could potentially result in infections such as pneumonia, sinusitis and disseminated infections. Riomet is not covered on Presbyterian formularies.
- **Long-Acting Beta Agonists (LABAs) and Inhaled Corticosteroids (ICS) – Drug Safety Communication [Dec. 20, 2017]:** The boxed warning regarding the risk of asthma related death was removed from the drug labels of ICS/LABA combination products. An FDA review of four large clinical trials showed that treating asthma with ICS/LABA combination products does not result in significantly more serious asthma related deaths compared to ICS treatment alone.
- **Clopidogrel Tablets USP, 75 mg by International Laboratories – Recall [Jan. 10, 2018]:** International Laboratories, LLC voluntarily recalled Lot# 117099A of Clopidogrel Tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product labeled as Clopidogrel Tablets US, 75 mg may contain Simvastatin Tablets, USP 10 mg, rather than Clopidogrel.



Presbyterian Health Plan, Inc.  
Provider Network Management  
P.O. Box 27489  
Albuquerque, NM 87125-7489  
[www.phs.org](http://www.phs.org)

PRESRT STD  
U.S. Postage  
PAID  
Albuquerque, NM  
Permit No. 1971

## Contact Us

The changes to our formularies are based on requests from our practitioners and by the recommendations of the P&T Committee. We value your input. If you have any concerns, please contact the Pharmacy Director, Chad Valdez, RPh, at [cvaldez4@phs.org](mailto:cvaldez4@phs.org) or (505) 923-5530. You may also contact the author of this newsletter, Kendra Ward, PharmD, at [kward2@phs.org](mailto:kward2@phs.org) or (505) 923-6967, Monday through Friday from 8 a.m. to 5 p.m., or email the ASK PHP P&T mailbox at [askphppt@phs.org](mailto:askphppt@phs.org).